FINANCIAL INSTRUMENTS

3 Months Ended

Mar. 31, 2022

Investments, All Other Investments [Abstract]

Cash, Cash Equivalents, and Investments

The following tables summarize the Company’s cash and available-for-sale marketable securities’ amortized cost, gross unrealized gains, gross unrealized losses, allowance for credit loss, and fair value by significant investment category reported as cash and cash equivalents, short-term investments, or long-term investments as of March 31, 2022 and December 31, 2021 (in millions):


											Reported as:
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Allowance for Credit Loss		Fair Value		Cash and Cash Equivalents		Short- term Investments		Long- term Investments
March 31, 2022
Cash	$	579.4	$	—	$	—	$	—	$	579.4	$	579.4	$	—	$	—
Level 1:
Money market funds	491.6		—		—		—		491.6		491.6		—		—
U.S. treasuries	3,599.5		0.9		(71.8)		—		3,528.6		12.0		1,329.3		2,187.3
Subtotal	4,091.1		0.9		(71.8)		—		4,020.2		503.6		1,329.3		2,187.3
Level 2:
Commercial paper	581.3		—		—		—		581.3		16.2		565.1		—
Corporate debt securities	2,554.6		0.3		(53.3)		(1.1)		2,500.5		3.9		770.0		1,726.6
U.S. government agencies	541.3		—		(13.5)		—		527.8		—		140.0		387.8

Municipal securities	196.9		0.1		(4.4)		—		192.6		—		78.1		114.5
Subtotal	3,874.1		0.4		(71.2)		(1.1)		3,802.2		20.1		1,553.2		2,228.9



Total assets measured at fair value	$	8,544.6	$	1.3	$	(143.0)	$	(1.1)	$	8,401.8	$	1,103.1	$	2,882.5	$	4,416.2


											Reported as:
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Allowance for Credit Loss		Fair Value		Cash and Cash Equivalents		Short- term Investments		Long- term Investments
December 31, 2021
Cash	$	572.3	$	—	$	—	$	—	$	572.3	$	572.3	$	—	$	—
Level 1:
Money market funds	696.6		—		—		—		696.6		696.6		—		—
U.S. treasuries	3,429.1		6.3		(15.4)		—		3,420.0		17.0		1,100.3		2,302.7
Subtotal	4,125.7		6.3		(15.4)		—		4,116.6		713.6		1,100.3		2,302.7
Level 2:
Commercial paper	717.7		—		—		—		717.7		—		717.7		—
Corporate debt securities	2,485.6		2.7		(11.9)		—		2,476.4		5.0		886.7		1,584.7
U.S. government agencies	526.1		0.2		(2.9)		—		523.4		—		137.8		385.6

Municipal securities	213.4		0.7		(1.0)		—		213.1		—		70.6		142.5
Subtotal	3,942.8		3.6		(15.8)		—		3,930.6		5.0		1,812.8		2,112.8



Total assets measured at fair value	$	8,640.8	$	9.9	$	(31.2)	$	—	$	8,619.5	$	1,290.9	$	2,913.1	$	4,415.5

The following table summarizes the contractual maturities of the Company’s cash equivalents and available-for-sale investments (excluding cash and money market funds), as of March 31, 2022 (in millions):


	Amortized Cost		Fair Value
Mature in less than one year	$	2,924.3	$	2,914.6
Mature in one to five years	4,549.3		4,416.2

Total	$	7,473.6	$	7,330.8

Actual maturities may differ from contractual maturities, because certain borrowers have the right to call or prepay certain obligations. Realized gains and losses recognized on the sale of investments were not material for any of the periods presented.

The following tables present the breakdown of the available-for-sale debt securities that have been in a continuous unrealized loss position deemed to be temporary, aggregated by investment category, as of March 31, 2022, and December 31, 2021 (in millions):


	March 31, 2022
	Less than 12 months				More than 12 months				Total
	Fair Value		Gross Unrealized Losses		Fair Value		Gross Unrealized Losses		Fair Value		Gross Unrealized Losses
U.S. treasuries	$	2,807.4	$	(59.6)	$	303.5	$	(12.2)	$	3,110.9	$	(71.8)
Commercial paper	6.9		—		—		—		6.9		—
Corporate debt securities	1,935.7		(49.2)		78.5		(4.1)		2,014.2		(53.3)
U.S. government agencies	506.9		(12.9)		10.9		(0.6)		517.8		(13.5)
Municipal securities	165.2		(4.4)		—		—		165.2		(4.4)
Total	$	5,422.1	$	(126.1)	$	392.9	$	(16.9)	$	5,815.0	$	(143.0)


	December 31, 2021
	Less than 12 months				More than 12 months				Total
	Fair Value		Gross Unrealized Losses		Fair Value		Gross Unrealized Losses		Fair Value		Gross Unrealized Losses
U.S. treasuries	$	2,596.3	$	(15.4)	$	—	$	—	$	2,596.3	$	(15.4)
Commercial paper	4.0		—		—		—		4.0		—
Corporate debt securities	1,687.9		(11.9)		—		—		1,687.9		(11.9)
U.S. government agencies	412.5		(2.9)		—		—		412.5		(2.9)
Municipal securities	156.0		(1.0)		—		—		156.0		(1.0)
Total	$	4,856.7	$	(31.2)	$	—	$	—	$	4,856.7	$	(31.2)

The Company’s investment portfolio at any point in time contains available-for-sale debt securities including investments in U.S. treasury and U.S. government agency securities, taxable and tax-exempt municipal notes, corporate notes and bonds, commercial paper, non-U.S. government agency securities, cash deposits, and money market funds. The Company segments its portfolio based on the underlying risk profiles of the securities and has a zero loss expectation for U.S. treasury and U.S. government agency securities. The basis for this assumption is that these securities have consistently high credit ratings by rating agencies, have a long history with no credit losses, are explicitly guaranteed by a sovereign entity, which can print its own currency, and is a currency that is routinely held by central banks, used in international commerce, and commonly viewed as a reserve currency. The Company regularly reviews the securities in an unrealized loss position and evaluates the current expected credit loss by considering factors such as historical experience, market data, issuer-specific factors, and current economic conditions. For the three months ended March 31, 2022, the credit losses related to available-for-sales debt securities were not material.

The Company determined these unrealized losses to be temporary. Factors considered in determining whether a loss is temporary included the length of time and extent to which the investment’s fair value has been less than the cost basis, the financial condition and near-term prospects of the investee, the extent of the loss related to credit of the issuer, the expected cash flows from the security, the Company’s intent to sell the security, and whether or not the Company will be required to sell the security before the recovery of its amortized cost. As of March 31, 2022, the Company did not intend to sell any of the debt

securities included in the table above, and it is not more likely than not that the Company will be required to sell any of these securities before recovery of the unrealized losses, which may be at maturity.

Equity Investments

The Company holds equity investments with readily determinable fair values and equity investments without readily determinable fair values. The Company generally recognizes equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.

The following table is a summary of the activity related to equity investments (in millions):


									Reported as:
	December 31, 2021 Carrying Value		Changes in Fair Value (1)		Sales/Purchases		March 31, 2022 Carrying Value		Prepaids and other current assets		Intangible and other assets, net
Equity investments with readily determinable value (Level 1)	$	26.9	$	(17.2)	$	—	$	9.7	$	9.7	$	—
Equity investments without readily determinable value (Level 2)	$	15.6	$	(0.1)	$	20.0	$	35.5	$	—	$	35.5

(1) Recorded in Interest and other income (expense), net.

In September 2021, Broncus Holding Corporation (“Broncus”) completed an initial public offering (“IPO”) of common shares on the Stock Exchange of Hong Kong. Upon completion of its IPO, the Company’s preferred shares of Broncus were converted into common shares, which have a readily determinable value (Level 1). The Company was restricted from selling these shares for a period of six months. For the three months ended March 31, 2022, we recognized an unrealized loss on this investment of $17.2 million reflected in changes in fair value for Level 1 equity investments, which was reflected in Interest and other income (expense), net.

There were no decreases in fair value reflected in net income due to impairments.

Foreign Currency Derivatives

The objective of the Company’s hedging program is to mitigate the impact of changes in currency exchange rates on net cash flow from foreign currency-denominated sales, expenses, intercompany balances, and other monetary assets or liabilities denominated in currencies other than the U.S. dollar (“USD”). The terms of the Company’s derivative contracts are generally twelve months or shorter. The derivative assets and liabilities are measured using Level 2 fair value inputs.

Cash Flow Hedges

The Company enters into currency forward contracts as cash flow hedges to hedge certain forecasted revenue transactions denominated in currencies other than the USD, primarily the Euro (“EUR”), the British Pound (“GBP”), the Japanese Yen (“JPY”), and the Korean Won (“KRW”). The Company also enters into currency forward contracts as cash flow hedges to hedge certain forecasted expense transactions denominated in EUR and the Swiss Franc (“CHF”).

For these derivatives, the Company reports the unrealized after-tax gain or loss from the hedge as a component of accumulated other comprehensive income/(loss) in stockholders’ equity and reclassifies the amount into earnings in the same period in which the hedged transaction affects earnings. The amounts reclassified to revenue and expenses related to the hedged transactions and the ineffective portions of cash flow hedges were not material for the periods presented.

Other Derivatives Not Designated as Hedging Instruments

Other derivatives not designated as hedging instruments consist primarily of forward contracts that the Company uses to hedge intercompany balances and other monetary assets or liabilities denominated in currencies other than the USD, primarily the EUR, GBP, JPY, KRW, CHF, Indian Rupee ("INR"), Mexican Peso ("MXN"), Chinese Yuan ("CNY"), and New Taiwan Dollar ("TWD").

These derivative instruments are used to hedge against balance sheet foreign currency exposures. The related gains and losses were as follows (in millions):


	Three Months Ended March 31,
	2022		2021
Recognized gains/(losses) in Interest and other income (expense), net	$	6.8	$	7.4
Foreign exchange gains/(losses) related to balance sheet re-measurement	$	(10.1)	$	(7.1)

Additionally, in January 2021, the Company settled a collar contract previously entered into to hedge its equity investment in Teladoc Health, Inc. For the three months ended March 31, 2021, a loss of $7.5 million was recognized in Interest and other income (expense), net.

The notional amounts for derivative instruments provide one measure of the transaction volume. Total gross notional amounts (in USD) for outstanding derivatives and the aggregate gross fair value at the end of each period were as follows (in millions):


	Derivatives Designated as Hedging Instruments				Derivatives Not Designated as Hedging Instruments
	March 31, 2022		December 31, 2021		March 31, 2022		December 31, 2021
Notional amounts:
Forward contracts	$	186.0	$	181.2	$	330.0	$	318.8
Gross fair value recorded in:
Prepaids and other current assets	$	6.9	$	5.7	$	6.8	$	6.9
Other accrued liabilities	$	0.4	$	0.5	$	1.9	$	0.8